{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000067","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.025779+00:00","generated_at":"2026-05-31T11:48:26.947581+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Keros Therapeutics reports Q2 2024 net loss of $45.3M; cash runway into 2027","bullets":["Net loss of $45.3M in Q2 2024, up from $37.5M in Q2 2023 due to increased R&D spend.","R&D expenses $40.5M (Q2 2024) vs $32.5M (Q2 2023); G&A $10.0M vs $8.8M.","Cash and equivalents $405.9M as of June 30, 2024, expected to fund operations into 2027.","Elritercept (KER-050) positive regulatory/data updates; cibotercept (KER-012) Phase 2 PAH enrollment to complete Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000067","json":"https://secwatch.observer/filing/0001664710-24-000067.json","markdown":"https://secwatch.observer/filing/0001664710-24-000067.md","text":"https://secwatch.observer/filing/0001664710-24-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000067/0001664710-24-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000067/kros-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:48:26.947581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}